Gyre Therapeutics, Inc. (GYRE) Operating Margin
- Operating margin · 12 months: Value -20.17%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -20.17% | Operating income / revenue. Period ending 2026-06-30. $-22.15M ÷ $109.82M × 100 ≈ -20.17% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -22.15M USD | Operating Income (Loss) |
| Revenue | 109.82M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.81M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-22.15M | $109.82M | $6.81M | (m) | (m) | -20.17% |
| 2026-03-31 | $-141.00K | $117.05M | $5.75M | $17.34M | (m) | -0.12% |
| 2025-12-31 | $11.49M | $116.59M | $5.42M | $13.70M | (m) | 9.85% |
| 2025-09-30 | $12.03M | $107.27M | $4.85M | $12.60M | (m) | 11.22% |
| 2025-06-30 | $9.34M | $102.19M | $4.18M | $13.01M | (m) | 9.14% |
| 2025-03-31 | $10.37M | $100.64M | $3.80M | $12.94M | (m) | 10.30% |
| 2024-12-31 | $16.16M | $105.76M | $3.88M | $12.02M | (m) | 15.28% |
| 2024-09-30 | $-76.07M | $105.03M | $3.96M | (m) | (m) | -72.42% |
| 2024-06-30 | $-67.53M | $111.59M | $4.18M | (m) | (m) | -60.52% |
| 2024-03-31 | $-65.82M | $115.69M | $4.49M | (m) | (m) | -56.90% |
| 2023-12-31 | $-67.23M | $113.45M | $4.64M | (m) | (m) | -59.26% |
| 2023-09-30 | $-44.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-47.80M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $6.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-8.61M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $11.35M | (m) | (m) | $28.51M | (m) | (m) |
| 2022-06-30 | $-8.71M | (m) | (m) | $48.06M | (m) | (m) |
| 2022-03-31 | $-80.16M | $6.67M | (m) | $61.58M | (m) | -1202.66% |
| 2021-12-31 | $-87.89M | $7.34M | (m) | $68.89M | (m) | -1197.79% |
| 2021-09-30 | $-86.42M | $6.93M | (m) | $67.31M | (m) | -1247.25% |
| 2021-06-30 | $-77.29M | $5.52M | (m) | $59.21M | (m) | -1399.47% |
| 2021-03-31 | $-74.74M | $6.05M | (m) | $56.72M | (m) | -1235.58% |
| 2020-12-31 | $-57.37M | $20.95M | (m) | $52.98M | (m) | -273.87% |
| 2020-09-30 | $-52.52M | (m) | (m) | $49.21M | (m) | (m) |
| 2020-06-30 | $-49.61M | (m) | (m) | $46.89M | (m) | (m) |
| 2020-03-31 | $-46.63M | (m) | (m) | $45.10M | (m) | (m) |
| 2019-12-31 | $-57.28M | (m) | (m) | $43.86M | (m) | (m) |
| 2019-09-30 | $-54.97M | (m) | (m) | $41.30M | (m) | (m) |
| 2019-06-30 | $-50.12M | (m) | (m) | $36.95M | (m) | (m) |
| 2019-03-31 | $-42.86M | (m) | (m) | $29.73M | (m) | (m) |
| 2018-12-31 | $-33.82M | $6.00K | (m) | $21.47M | (m) | -563700.00% |
| 2018-09-30 | $-27.97M | (m) | (m) | $16.80M | (m) | (m) |
| 2018-06-30 | $-25.50M | (m) | (m) | $15.03M | (m) | (m) |
| 2018-03-31 | $-24.33M | (m) | (m) | $14.56M | (m) | (m) |
| 2017-12-31 | $-21.82M | (m) | (m) | $12.85M | (m) | (m) |
| 2017-09-30 | $-21.21M | (m) | (m) | $12.40M | (m) | (m) |
| 2017-06-30 | $-21.05M | (m) | (m) | $11.99M | (m) | (m) |
| 2017-03-31 | $-20.02M | (m) | (m) | $11.33M | (m) | (m) |
| 2016-12-31 | $-20.42M | (m) | (m) | $11.55M | (m) | (m) |
| 2016-09-30 | $-19.88M | (m) | (m) | $10.21M | (m) | (m) |
| 2016-06-30 | $-18.05M | (m) | (m) | $8.30M | (m) | (m) |
| 2016-03-31 | $-15.34M | (m) | (m) | $6.86M | (m) | (m) |
| 2015-12-31 | $-13.80M | (m) | (m) | $5.96M | (m) | (m) |
| 2015-09-30 | $-10.92M | (m) | (m) | $5.59M | (m) | (m) |
| 2015-06-30 | $-20.94M | $212.00K | (m) | $7.99M | (m) | -9876.89% |
| 2015-03-31 | $-24.78M | $248.00K | (m) | $12.76M | (m) | -9992.34% |
| 2014-12-31 | $-29.71M | $275.00K | (m) | $19.50M | (m) | -10805.09% |
| 2014-09-30 | $-38.29M | $241.00K | (m) | $27.90M | (m) | -15888.38% |
| 2014-06-30 | $-46.45M | $216.00K | (m) | $35.55M | (m) | -21504.17% |
| 2014-03-31 | $-50.70M | $180.00K | (m) | $39.60M | (m) | -28165.56% |
| 2013-12-31 | $-47.22M | $3.63M | (m) | $38.84M | (m) | -1301.07% |
| 2013-09-30 | $-50.17M | $4.13M | (m) | $40.43M | (m) | -1215.90% |
| 2013-06-30 | $-45.12M | $4.89M | (m) | $36.55M | (m) | -921.95% |
| 2013-03-31 | $-18.40M | $38.54M | (m) | $39.61M | (m) | -47.74% |
| 2012-12-31 | $-8.14M | $57.86M | (m) | $49.09M | (m) | -14.06% |
| 2012-09-30 | $-2.02M | $76.22M | (m) | $62.82M | (m) | -2.65% |
| 2012-06-30 | $-3.26M | $94.40M | (m) | $81.83M | (m) | -3.45% |
| 2012-03-31 | $-20.06M | $81.50M | (m) | $89.50M | (m) | -24.61% |
| 2011-12-31 | $-9.74M | $97.64M | (m) | $95.22M | (m) | -9.98% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $13.12M | $85.71M | (m) | $64.55M | (m) | 15.30% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-40.33M | $25.06M | (m) | $40.18M | (m) | -160.90% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |